Document is current
Any future updates will be listed below
-
Authors
Manns, Michael P. https://orcid.org/0000-0002-4485-8856
Bergquist, Annika https://orcid.org/0000-0002-3858-6241
Karlsen, Tom H. https://orcid.org/0000-0002-8289-9931
Levy, Cynthia
Muir, Andrew J. https://orcid.org/0000-0002-0206-1179
Ponsioen, Cyriel
Trauner, Michael https://orcid.org/0000-0002-1275-6425
Wong, Grace https://orcid.org/0000-0002-2863-9389
Younossi, Zobair M.
- License Information
-
More Information
Article History
Accepted: 7 February 2025
First Online: 13 March 2025
Competing interests
: M.P.M. received grants and or consulting fees from Falk Pharma GmbH (Freiburg, Germany), Gilead Sciences, Intercept and Novartis. A.B. received research grants from Gilead Sciences and is part of the Advisory Board Ipsen. T.H.K. received consulting fees from MSD, Albireo and Falk Pharma, and is Board Member and President Elect at Biomed Alliance. C.L. has received research grants and consulting fees from Gilead Science, Ipsen, High Tide, Mirum, Escient, Chemomab and Intercept. A.J.M. received research grants from Gilead Science and Pilant Therapeutics. C.P. received grants from Gilead Sciences, NGM and Perspectum, consultancy fees from Pliant and Chemomab, and speaker’s fees from Tillotts. M.T. has received research grants from Albireo, Alnylam, Cymabay, Falk, Genentech, Gilead, Intercept, MSD, Takeda and Ultragenyx, and travel grants from Abbvie, Falk, Gilead, Intercept and Jannsen. He has advised for Abbvie, Albireo, Agomab, BiomX, Boehringer Ingelheim, Chemomab, Falk Pharma GmbH, Genfit, Gilead, Hightide, Ipsen, Intercept, Janssen, MSD, Novartis, Phenex, Pliant, Regulus, Siemens and Shire, and has served as speaker for Albireo, BMS, Boehringer Ingelheim, Falk, Gilead, Intercept, Ipsen, Madrigal and MSD. He is a co-inventor (service inventions) of patents for the medical use of norUDCA (nor-ursodeoxycholic acid/norucholic acid)/NCA filed by the Medical Universities of Graz and Vienna. G.W. has served as an advisory committee member for AstraZeneca, Gilead Sciences, GlaxoSmithKline and Janssen, and as a speaker for Abbott, AbbVie, Ascletis, Bristol-Myers Squibb, Echosens, Gilead Sciences, Janssen and Roche. She has also received a research grant from Gilead Science. Z.M.Y. received research funding and/or serves as a consultant to Intercept, Cymabay, Boehringer Ingelheim, BMS, GSK, NovoNordisk, AstraZeneca, Ipsen, Siemens, Madrigal, Merck and Abbott.
